PCN208 COST-EFFECTIVENESS OF NIVOLUMAB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH INVOLVEMENT OF LYMPH NODES OR METASTATIC DISEASE WHO HAVE UNDERGONE COMPLETE RESECTION: AN ANALYSIS FROM A SWISS HEALTHCARE SYSTEM PERSPECTIVE

Autor:	A. Amadi, S. Teitsson, G. Strittmatter, I. Orsini, M. Augusto, C. Oniangue-Ndza
Rok vydání:	2019
Předmět:	Oncology medicine.medical_specialty Cost effectiveness business.industry Health Policy Melanoma medicine.medical_treatment Perspective (graphical) Public Health Environmental and Occupational Health Disease medicine.disease Complete resection Internal medicine medicine Lymph Nivolumab business Adjuvant
Zdroj:	Value in Health. 22:S476
ISSN:	1098-3015
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::8f40b960a9da17ea5ae414f37fb7b123 https://doi.org/10.1016/j.jval.2019.09.404 Zobrazit plný text záznamu Full Text from ScienceDirect